Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Expected to Post Earnings of $16.70 Per Share

Brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings per share of $16.70 for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $21.71 and the lowest is $7.64. Regeneron Pharmaceuticals reported earnings of $9.53 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 75.2%. The business is expected to report its next quarterly earnings results on Friday, February 4th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $67.30 per share for the current year, with EPS estimates ranging from $43.09 to $73.70. For the next fiscal year, analysts expect that the firm will report earnings of $46.98 per share, with EPS estimates ranging from $35.38 to $65.41. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $9.81 by $5.56. The firm had revenue of $3.45 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 50.38% and a net margin of 51.65%. The company’s quarterly revenue was up 50.5% compared to the same quarter last year. During the same period in the previous year, the business posted $7.68 EPS.

Several equities analysts have recently issued reports on REGN shares. Oppenheimer boosted their target price on Regeneron Pharmaceuticals from $725.00 to $825.00 and gave the stock an “outperform” rating in a research report on Friday, August 6th. Benchmark lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 5th. Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $675.00 to $690.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 15th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $571.00 to $617.00 and gave the stock an “equal weight” rating in a research report on Friday, November 5th. Finally, Barclays boosted their target price on Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $703.59.

In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $576.75, for a total transaction of $576,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George L. Sing sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $657.50, for a total value of $1,315,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,079 shares of company stock valued at $30,010,914. Insiders own 11.84% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Heritage Wealth Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $30,000. Gleason Group Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Arkadios Wealth Advisors raised its stake in Regeneron Pharmaceuticals by 96.6% in the 2nd quarter. Arkadios Wealth Advisors now owns 57 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Evoke Wealth LLC raised its stake in Regeneron Pharmaceuticals by 427.3% in the 3rd quarter. Evoke Wealth LLC now owns 58 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 47 shares during the period. Finally, Sandy Spring Bank raised its stake in Regeneron Pharmaceuticals by 416.7% in the 2nd quarter. Sandy Spring Bank now owns 62 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 50 shares during the period. Institutional investors own 82.08% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock traded down $1.14 during trading on Thursday, hitting $648.18. 545,233 shares of the company were exchanged, compared to its average volume of 850,101. The firm has a market capitalization of $69.71 billion, a P/E ratio of 10.35, a price-to-earnings-growth ratio of 1.16 and a beta of 0.19. Regeneron Pharmaceuticals has a 1-year low of $441.00 and a 1-year high of $686.62. The firm’s fifty day moving average price is $606.80 and its 200 day moving average price is $588.14. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.71 and a quick ratio of 3.16.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Recommended Story: What is a CD ladder?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.